These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Sep 14, 2017Sierra Oncology to Host KOL Call with Dr. Thomas Helleday presenting "DNA Damage Response (DDR) Targets Beyond PARP"
Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today...
Aug 15, 2017
- Leading experts in DDR biology, chemistry and medicine to help maximize the potential clinical and commercial opportunities for Sierra's drug candidates – VANCOUVER, Aug. 15, 2017 /CNW/ -...
Aug 10, 2017
- On track to provide preliminary update from Chk1 inhibitor SRA737 clinical trials in early 2018 - - Phase 1 trials amended and enhanced to prospectively enroll patients with genetically-defined...
Aug 2, 2017
- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 1:55 pm ET on August 15, 2017 - VANCOUVER, Aug. 2, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug...
Jun 5, 2017Sierra Oncology Reports Encouraging Initial Progress from Ongoing Phase 1 Clinical Trials of Chk1 Inhibitor SRA737
- Presenting two posters describing innovative trial designs leveraging Chk1 synthetic lethality at the ASCO 2017 Annual Meeting - VANCOUVER, June 5, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ:...